Health is a fundamental human right and is essential for a sustainable economic and social development. Improve current and future generations health and well-being, reduce health inequalities, broaden access to high-quality care, strengthen public health and encourage public-private collaboration, enhance people centricity and engagement, ensure advanced training of healthcare professionals, boost R&D and facilitate access to innovation, are the strategic goals of the Health & Life Sciences industry.
Advanced scientific research, technological innovation and digital transformation are crucial means to fulfill these goals as they have a demonstrated capacity to improve the impact of care and cost-effectiveness. This endeavor calls for a profound redesign of health systems as their sustainability is challenged by many factors such as economic, social and environmental changes, aging population as well as expansion of chronic and infectious diseases as Covid-19. The pandemic has stressed health systems globally and impacted research organizations at an unprecedented scale. Therefore, the Health and Life Science industry now needs to collaborate with Governments to develop new approaches to respond to these pressures, moving from crisis response to more resilient models.
The commitment of the B20 Italy is to deliver impactful and applicable recommendations to help Governments and societies shape a new governance of the Health and Life Sciences industries and provide a brighter future for all.

Chair
Sergio Dompé is an entrepreneur in the biopharmaceutical sector, with a growing role in institutions and industry. A pionieer of biotech in Italy, where he launched the sector un the ‘80s he understood early on the value of biotechnologies for the Life Sciences industry. In 2018 Dompé’s Cenegermin,the first NGF-based biotech principle for the treatment of a rare eye disease, was recognized as Breakthrough Therapy Designation by the FDA. This important milestone was possible thanks to unabiding investments in R&D and in innovative production processes. More recently, Dompé has launched new initiatives in areas such as biotech (Philogen since 2004), artificial intelligence, robotics (Movendo Technology since 2017), new materials and nanotech (Directa Plus since 2016 and Materias since 2019). Over the years, Sergio Dompé has been involved with Institutions and Industry associations at different levels : President of Assobiotec (1998-2004); President of Farmindustria (2005-2011); President of CNR’s Evaluation Committee (2006-2011); Vice President of Assolombarda Life Sciences (since 2019). Among the honors and award received by Sergio Dompé’s in the scientific and institutional fields are: degrees honoris causa in Biotechnology with a focus on pharmaceuticals (University of Bologna, 1996), Medical Biotechnology (University of L’Aquila, 2005) and Pharmacy (Urbino University, 2010).

Deputy Chair
Guido Romeo is Corporate Communications Head at Dompé farmaceutici. A former journalist, he has been Editor in chief of Atomium–EISMD’s REIsearch project and Communications director of AI4People. A graduate from the University of Bologna, he holds a journalism degree from the Ecole Supérieure de Journalisme in Lille, France and a masters in communications. In 2004 he was Armenise-Harvard science-writer fellow at the Harvard School of Medicine. He tweets as @guidoromeo

Co-Chair
After studying economics at RWTH Aachen University of Cologne, Werner Baumann began his career at Bayer in 1988. He joined the Board of Management in 2010 as hief Financial Officer. From October 2014 until his appointment as Chairman of the Board of Management, he served as Chief Strategy and Portfolio Officer. On May 1, 2016, Werner Baumann became Chairman of the Board of Management (CEO) of Bayer AG.

Co-Chair
Sir Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension, which has discovered over 1000 gene loci for blood pressure. He served on the NICE Guideline Group for hypertension and was President of the British Hypertension Society (2009-2011).
He was Director of the William Harvey Research Institute between 2002 and 2020 and was elected a Fellow of the Academy of Medical Sciences in 2008. Since 2008 he directs the National Institute for Health Research Cardiovascular Biomedical Research Unit and Centre at Barts. Between 2010 and 2015 he co-led the merger of three hospitals in North London to create the new £400 million Barts Heart Centre. He has won the Lily Prize of the British Pharmacology Society, the Bjorn Folkow Award of the European Society of Hypertension 2016 and the Franz Volhard Award of the International Society of Hypertension in 2018. In 2013 he became an NIHR Senior Investigator and was appointed as the Chief Scientist for Genomics England (100,000 Genomes Project. Sir Mark was awarded a Knighthood in the June 2019 Queen’s Birthday Honours List for services to the 100,000 Genomes Project.

Co-Chair
Geoff Martha is Chairman of the Board of Directors and Chief Executive Officer of Medtronic, the world’s leading medical technology company, with more than 90,000 employees and operations reaching more than 150 countries. Medtronic offers technologies and solutions to treat a wide range of medical conditions, including cardiac and vascular diseases, respiratory, neurological and spinal conditions, diabetes, and more.
Prior to his role as Chairman and CEO, Geoff held an array of global leadership positions at Medtronic, including President, leading Medtronic’s operating groups and regions. He served as EVP and President of Medtronic’s Restorative Therapies Group (RTG), where he had global responsibility for RTG’s four divisions. Geoff also served as SVP of Strategy and Business Development, leading the $10 billion acquisition and integration of Covidien — the largest medical technology acquisition in the history of the industry. An ardent supporter of philanthropic and diversity initiatives, Geoff is a member of the Medtronic Foundation Board of Directors and serves as Medtronic’s Executive Sponsor to FIRST Robotics. He serves on the board of directors for Children’s HeartLink and the Northside Achievement Zone. Geoff also serves on the Development Council for Penn State’s College of Liberal Arts. Prior to joining Medtronic, Geoff held several leadership positions in his 19-year career with GE, including the role of Managing Director of Business Development at GE Healthcare and several roles with GE Capital. He received a bachelor’s degree in Finance as a member of the Scholar’s Program from Pennsylvania State University, where he graduated with highest honors.

Co-Chair
Leon was appointed Executive Vice-President, Asia Pacific in January 2017 and assumed responsibility for the growth and performance of AstraZeneca’s commercial businesses in all our International markets in April. These markets include China, Asia Area, Australia & New Zealand as well as Latin America and Brazil, Russia and Eurasia and the Middle East and Africa. Leon joined AstraZeneca China in 2013 as a Vice-President and became President in 2014. Under his leadership China became AstraZeneca’s second-largest market worldwide. Leon has twenty years of experience in the pharmaceutical industry, including a series of positions of increasing responsibility in marketing and business leadership at Roche where he was a Business Unit Vice-President. He is Council Vice Chairman of the Shanghai Association of Foreign Investment, Executive Committee Member responsible for Pricing of the R&D based Pharmaceutical Association Committee under the China Association of Enterprises with Foreign Investment, Corporate Advisory Board Member of China Europe International Business School and guest lecturer at Shanghai International Studies University. He holds a Bachelor of Arts from Shanghai International Studies University and an EMBA from China Europe International Business School.

Task Force Manager
Luca Del Vecchio has worked in the Territorial Policies, Innovation and Education Area of Confindustria since April 2013. His work experience in Confindustria started in June 1989. Since then he has held the position of Operations Co-Ordinator for Confindustria’s Health Project and joined the unit titled “Social Security, Welfare and Health Care” in May 2001, until March 2005. Mr. Del Vecchio is also the Vice President for FASI, the supplementary health care fund for executives of Italian companies. Mr. Del Vecchio also serves as one of the reviewers for the MIUR and CRUI project on life sciences since 2016, and he has participated in the proceedings of Confindustria’s Committee on Digital Economy since 2013. Moreover, he has worked in close cooperation with the Italian government for a more thorough analysis of the problems connected to the delayed public administration payments of the health sector. He became a member of the roster of experts of the Italian Ministry of Health in the field of supplementary health funds, starting from 2007 until 2009.
In 1991 Mr. Del Vecchio was awarded a British Council Scholarship at Birmingham University. In 1991 and 1996 he served as Expert of the European Commission (DG XII) for the evaluation of research and innovation projects proposed by SMEs.